Time filter

Source Type

Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 110^(6 )to 110^(8). Activated platelets release and transfer adhesion factors to the surface of platelet cells, and trap stromal vascularity inflammatory cells from inflammated and damaged place, and the stromal vascularity inflammatory cells are eliminated through the circulatory system to alleviate inflammation. The fixed shape-changed platelets are able to alleviate inflammation and sustainable for longer storage duration.


A method for measuring the amount of sialic acid in immunoglobulin G and immunoglobulin G anti-ds DNA antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin G in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin G. Also, using a mouse monoclonal antibody immunoglobulin G as a standard, which is diluted from 1000 ng/ml to 15.625 ng/ml in phosphate buffered saline (PBS), produces good results. The method for measuring the amount of sialic acid in immunoglobulin G anti-ds DNA antibodies has never been done and the present invention produces good results as well.


A method for measuring the amount of sialic acid in immunoglobulin G and immunoglobulin G anti-ds DNA antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin G in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin G. Also, using a mouse monoclonal antibody immunoglobulin G as a standard, which is diluted from 1000 ng/ml to 15.625 ng/ml in phosphate buffered saline (PBS), produces good results. The method for measuring the amount of sialic acid in immunoglobulin G anti-ds DNA antibodies has never been done and the present invention produces good results as well.


A protein vaccine composition of protection against pneumococcal infection in a subject is disclosed. The vaccine composition comprises three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of S. pneumoniae strains CGSP14, wherein administration of the recombinant full-length- and partial-pneumococcal neuraminidases elicits an immune response to all serotypes of S. pneumoniae. In one embodiment, the method further includes a step of adding adjuvants to enhance the immune response. The method also comprises a step of using passive antibodies, wherein said passive antibodies are anti-neuraminidase antibodies generated from neuraminidases-immunized animals against NanA, NanB, and NanC. Meanwhile, this invention also provides a method for the molecular diagnosis of pneumococcal infection, and a method of detecting neuraminidase activity.


Patent
Chang Gung Medical Foundation | Date: 2012-06-12

A natural orifice transluminal endoscopic surgery (NOTES) device is provided with a puncture needle including a puncture end, an intermediate protruding safety stud, and a positioning projection on an outer surface; dilator sheaths each including tapered first diameters, an insert member at one end, a limiting shoulder at the other end, a positioning protrusion on an outer surface, and a groove on an inner surface; working sheaths each having a plurality of tapered second diameters and including a positioning protuberance on an outer surface and a trough on an inner surface; and a tool member including a shaft having a graduation on an outer surface, and an operating head threadedly secured to the shaft.


A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of S. pneumoniae strains CGSP14, wherein administration of the recombinant pneumococcal neuraminidases elicits an immune response to S. pneumoniae, and treats the subject. In one embodiment, the method further includes a step of adding adjuvants to enhance the immune response. The method also includes a step of using passive antibodies, wherein said passive antibodies are anti-neuraminidase antibodies generated from neuraminidases-immunized humanized animals: NanA, NanB, and NanC. Meanwhile, this invention also provides a method for the molecular diagnosis of pneumococcal infection.


Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 110^(6 )to 110^(8). Activated platelets release and transfer adhesion factors to the surface of platelet cells, and trap stromal vascularity inflammatory cells from inflammated and damaged place, and the stromal vascularity inflammatory cells are eliminated through the circulatory system to alleviate inflammation. The fixed shape-changed platelets are able to alleviate inflammation and sustainable for longer storage duration.


The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer.


The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer.


The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer.

Loading Chang Gung Medical Foundation collaborators
Loading Chang Gung Medical Foundation collaborators